Drug news
Farxiga to enter Type 1 Diabetes trial-AstraZeneca + Ono
AstraZeneca has announced a new Phase III study to determine if adding Farxiga ( dapagliflozin ) to insulin is a safe and effective therapy to improve glycemic control in patients with Type 1 Diabetes and is currently recruiting participants. Target enrollment is 768 patients.